🇺🇸 FDA

Company profile · Sponsor

Aclaris

Aclaris Therapeutics

ACRS · NYSE pharma WAYNE, PA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

Aclaris (ACRS) is a pharma company. headquartered in WAYNE, PA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker ACRS
Exchange NYSE
Company type pharma
Headquarters WAYNE, PA, USA
SEC CIK 0001557746

Pipeline (24)

Search pipeline →

  1. A-101

    Aclaris

    Common Wart

    phase 3 small molecule completed

    2 trials

  2. A-101 Solution

    Aclaris

    Seborrheic Keratosis

    phase 3 small molecule completed

    3 trials

  3. Active

    Aclaris

    Common Wart

    phase 3 small molecule completed

    1 trial

  4. A-101

    Aclaris

    Seborrheic Keratosis

    phase 2 small molecule completed

    2 trials

  5. A-101 25%

    Aclaris

    Seborrheic Keratosis (SK)

    phase 2 small molecule completed

    1 trial

  6. A-101 Solution 40

    Aclaris

    Common Warts

    phase 2 small molecule completed

    1 trial

  7. A-101 Topical Solution

    Aclaris

    Common Wart

    phase 2 small molecule completed

    2 trials

  8. A-101 Topical Solution 40%

    Aclaris

    Dermatosis Papulosa Nigra

    phase 2 small molecule completed

    1 trial

  9. A-101 Vehicle

    Aclaris

    Seborrheic Keratosis

    phase 2 small molecule completed

    1 trial

  10. ATI 502 0.46% Topical Solution

    Aclaris

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  11. ATI-045

    Aclaris

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. ATI-045, Placebo to ATI-045

    Aclaris

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  13. ATI-1777

    Aclaris

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. ATI-1777 2.0% w/w

    Aclaris

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  15. ATI-2138

    Aclaris

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  16. ATI-450

    Aclaris

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  17. ATI-450

    Aclaris

    Cryopyrin-Associated Periodic Syndrome

    phase 2 small molecule terminated

    1 trial

  18. ATI-450

    Aclaris

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  19. ATI-450

    Aclaris

    Psoriatic Arthritis

    phase 2 small molecule terminated

    1 trial

  20. ATI-450 50 mg oral tablet BID

    Aclaris

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  21. ATI-50002

    Aclaris

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

  22. ATI-50002

    Aclaris

    Alopecia Areata

    phase 2 small molecule completed

    1 trial

  23. ATI-50002 high dose

    Aclaris

    Alopecia Areata

    phase 2 small molecule terminated

    1 trial

  24. ATI-50002 topical solution

    Aclaris

    Vitiligo

    phase 2 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. hydrogen peroxide

    ESKATA

    TOPICAL approved

Patents (8)

Search patents →

  1. US 12403141

    Deuterated MK2 pathway inhibitors and methods of using the same

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12297203

    Pyrrolopyrimidine ITK inhibitors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12281111

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11844801

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11820775

    Pyrrolopyrimidine ITK inhibitors

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11739086

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10981906

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aclaris?

Aclaris (ACRS) is a pharma company. headquartered in WAYNE, PA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Aclaris sponsor?

We track 24 ClinicalTrials.gov-linked programs for Aclaris, including A-101 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aclaris company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.